Intrathecal administration of ST2 antibody suppressed the pain behavior, suggesting that IL-33/ST2 might play a critical role in cancer-induced pain and could serve as a putative target in bone cancer pain management [131]. This evidence concerns the gene IL33 and bone cancer.